Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | A2B543 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on A2B543, putative autologous T-cells expressing a chimeric antigen receptor (CAR) targeting MSLN (Jan 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| A2B543 | A2B-543|A2B 543 | MSLN Immune Cell Therapy 11 | Limited information is currently available on A2B543, putative autologous T-cells expressing a chimeric antigen receptor (CAR) targeting MSLN (Jan 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06051695 | Phase Ib/II | A2B543 A2B694 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) | Recruiting | USA | 0 |